title: [Efficacy of intrathecal baclofen in the treatment of spasticity in stroke].
abstract: OBJECTIVE
  To determine whether intrathecal administration of baclofen reduced spastic hypertonia in a hemiplegic patient after hemorrhagic stroke.
  
  
  METHODS
  A trial of intrathecal administration of baclofen was carried out with bolus injections of 50 and 75 microg baclofen and clinical and functional evaluation (Aschworth, articular amplitude) before and after injection in a patient with hemorrhagic stroke. After these trials, the placement of a pump was proposed to the patient.
  
  
  RESULTS
  Aschworth score improved from 4 to 3 on triceps, quadriceps and adductus, with functional improvement of gait quality and perimeter and position in the wheelchair. Cephalgia, present before the treatment, increased after the implantation of the pump. The patient had some ejaculation trouble with the treatment, as well as some neurological pains after the pump implantation but experienced no effect on upper limbs.
  
  
  CONCLUSIONS
  The intrathecal administration of baclofen has been used in some studies of hemiplegic patients, with reduced spasticity and improved the kinematic parameters of gait. The intrathecal baclofen administration could complement other treatment to control spasticity after stroke.
  
  
  CONCLUSIONS
  Intrathecal baclofen administration could be an interesting complementary therapeutic among patients with important spasticity not controlled by the usual treatments.
authors.affiliation: Service de médecine physique et de réadaptation, hôpital Reine-Hortense, boulevard Berthollet, 73100 Aix-les-Bains, France. dlamotte@ch-aix-les-bains.fr
authors.forename: D
authors.initials: D
authors.lastname: Lamotte
authors.forename: S
authors.initials: S
authors.lastname: Cantalloube
mesh_terms: D001418:Baclofen / Q000627:therapeutic use*; D006429:Hemiplegia / Q000150:complications; D006801:Humans; D015918:Infusion Pumps, Implantable; D007278:Injections, Spinal; D008297:Male; D008875:Middle Aged; D009125:Muscle Relaxants, Central / Q000627:therapeutic use*; D009128:Muscle Spasticity / Q000188:drug therapy* / Q000209:etiology*; D020521:Stroke / Q000150:complications*
chemical_list: D009125:Muscle Relaxants, Central; D001418:Baclofen